Merkel cell carcinoma (MCC) is a malignant neuroendocrine skin tumor frequently associated with the Merkel cell polyomavirus. Immune checkpoint therapy showed remarkable results, although not all patients are responsive to this therapy. Anti-tropomyosin receptor kinase A (TrkA)-targeted treatment has shown promising results in several tumor entities. Thirty-eight of 38 specimens expressed CK20 and synaptophysin on the MCC tumor cells (100% expression). Merkel cell polyomavirus was detected in 32 of 38 specimens (84%). Tropomyosin receptor kinase A was found in all 36 evaluable specimens on the tumor cells; 34 (94%) showed a weak and 2 (6%) showed a strong cytoplasmic expression. In addition, strongly positive perinuclear dots were observed in 30 of 36 specimens (83%).
M erkel cell carcinoma (MCC) is a rare, highly malignant, mostly asymptomatic, and rapidly expanding neuroendocrine tumor of the skin of older (>50 years) individuals that is frequently associated with Merkel cell polyomavirus, UV exposure, and immunosuppression. 1, 2 High incidence of local recurrence is characteristic, as is early regional lymph node and possible distant metastasis. 3 In stage IV disease, the 2-year survival rate is only 26%. 4 These characteristics illustrate the need for detection of tumor-specific pathways and possible therapeutic targets. Several mechanisms are known to be relevant in immune response in tumor tissue. For example, viral infection usually induces an immune response, and malignant tumors with viral infection, such as MCC, eventually necessitate effective ways of immune escape mechanisms to progress. The recent development of immune checkpoint inhibitors targeting programmed cell death protein 1 and programmed death ligand 1 have shown response rates of 56% in patients with MCC. 5 However, a substantial number of patients still do not show a response. Obviously, the programmed cell death protein 1 pathway (regulating the adaptive immune response) is not the only mechanism of immune escape in MCC. 6 Tropomyosin receptor kinase (Trk) pathway aberrations, including protein overexpression, have been reported in several cancer types, such as breast and colorectal cancer, and selective inhibition of Trk signaling has shown encouraging interim results in ongoing phase 2 trials. 7 In this study, we explored the expression and putative significance of TrkA as a potential mediator of cell survival and treatment target in patients with MCC.
Methods
The 
Histopathologic Evaluation
In total, 39 formalin-fixed and paraffin-embedded tumor samples were investigated. Deparaffinized sections were stained with hematoxylin-eosin. All cases were investigated for expression of cytokeratin 20, synaptophysin, and Merkel cell polyomavirus at a dilution of 1:50 (Santa Cruz Biotechnology) using standard protocols and were reviewed by 3 of us who were expert pathologists and dermatopathologists (U.W., C.R., and F.E.) to confirm the diagnosis of MCC. Immunostaining was performed manually using a rabbit monoclonal TrkA antibody at a dilution of 1:200 (Abcam). The identification and characterization of the expressing cells were performed based on histomorphologic criteria. For the identification of cells belonging to the mononuclear phagocyte system, additional CD68 
In 39 cases, the material was suitable for immunohistochemical analyses, which were performed in addition to routine hematoxylin-eosin staining. Thirty-eight of 38 MCCs (100%) expressed CK20 and synaptophysin on the tumor cells (Figure) . Merkel cell polyomavirus was detected in 32 of 38 evaluable specimens (84%).
Tropomyosin Receptor Kinase A Tumor cells were positive for TrkA in 36 of 36 patients (100%) with evaluable specimens, with a weak cytoplasmic expression in 34 (94%) and a strong cytoplasmic expression in 2 (6%). In addition, strongly positive perinuclear dots were observed in 30 of the 36 specimens (83%) (Figure) . Staining results were considered to be positive if more than 50% of the tumor cells expressed TrkA.
Inflammatory Infiltrate
The density of the tumor surrounding and infiltrating inflammatory cells was low in 17 of 39 specimens (44%), moderate in 16 (41%), and dense in 6 (15%). In all cases, CD68-positive cells were in a spindle cell configuration surrounding the tumor cell complexes.
Discussion
For the first time, to our knowledge, we describe the expression of TrkA in MCC. In all evaluable specimens in our study, TrkA was present on MCC tumor cells. Thus, the inhibition of TrkA seems to be an interesting target as a future treatment option. Completion of the studies is envisaged within the next 12 to 18 months. As we demonstrate in our present analysis, MCC tumor cells express TrkA and therefore could be ideal candidates for beneficial effects exerted by TrkA inhibition. The immune system is known to play a critical role in tumor defense and control. Thus, our attention was directed not only to TrkA expression but also to the immune infiltrate. We found that the MCC tumor tissue is surrounded by tumor-associated immune cells (TAIC) that express CD68. The term TAIC is used synonymously with interdigitating dendritic cells. Most likely, the CD68 + spindle cells detected in our analysis represent interdigitating dendritic cells, which are part of the antigen-presenting system and belong to the most potent stimulators for naive T lymphocytes. 15 We observed a rimming morphology of the TAIC around the tumor cell complexes, which is suggestive of an interaction between tumor cells and TAIC. Additional functional studies are required to elucidate whether a connection between the tumor and its microenvironment exists that might be a relevant factor for triggering this morphologic correlate. 
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Tropomyosin receptor kinase A, activated by its ligand nerve growth factor, may block T cells via the same pathways as programmed cell death protein 1 and programmed death ligand 1. 16, 17 Interaction between nerve growth factor and TrkA is responsible for the survival of neural cells. 18, 19 If cell survival is promoted by this interaction, it could also be an important mechanism for tumor cell survival.
Limitations
A limitation of the present study is the limited number of evaluable cases. Therefore, the validation of our results in an independent cohort would be of interest.
Conclusions
Our study shows for the first time, to our knowledge, the expression of TrkA on MCC tumor cells. Exploring anti-TrkA treatment could be interesting with respect to the high expression on tumor cells in patients with MCC. In addition, the morphologic finding of the arrangement of the TAIC rimming around the tumor is interesting and might be important for the understanding of immune escape mechanisms. Additional studies are necessary to confirm our findings and to elucidate the role of marker expression on tumor cells.
